Jorge A R Salvador

Scopus Author ID ResearcherID Loop profile Ciência ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 13

Top Topics

Structure Activity Relationship

Stem Cell Transplantation

Top Venues

Expert opinion on therapeutic patents

RSC medicinal chemistry

International journal of molecular sciences

This page only lists publications with an associated author ORCID identifier.

Publications

André T S Vicente, Jorge A R Salvador
PROteolysis-Targeting Chimeras (PROTACs) in leukemia: overview and future perspectives. MedComm 5 (6) (2024)
André T S Vicente, Jorge A R Salvador
PROteolysis-Targeting Chimeras (PROTACs) in leukemia: overview and future perspectives. MedComm 5 (6) (2024)
Romina A Guedes, Jorge H Grilo, Andreia Neves Carvalho, Pedro M P Fernandes, Ana S Ressurreição, Vanessa Brito, Adriana O Santos, Samuel M Silvestre, Eleonora Gallerani, Maria João Gama, Riccardo Gavioli, Jorge A R Salvador, Rita C Guedes
New Scaffolds of Proteasome Inhibitors: Boosting Anticancer Potential by Exploiting the Synergy of In Silico and In Vitro Methodologies. Pharmaceuticals (Basel, Switzerland) 16 (8) (2023)
André T S Vicente, Jorge A R Salvador
Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia - a patent review. Expert opinion on therapeutic patents (2023)
Laura D Carreira, Rita I Oliveira, Vânia M Moreira, Jorge A R Salvador
Ubiquitin-specific protease 7 (USP7): an emerging drug target for cancer treatment. Expert opinion on therapeutic targets (2023)
Bruno M F Gonçalves, Vanessa I S Mendes, Samuel M Silvestre, Jorge A R Salvador
Design, synthesis, and biological evaluation of new arjunolic acid derivatives as anticancer agents. RSC medicinal chemistry 14 (2) (2022)
Carlota Leonardo-Sousa, Andreia Neves Carvalho, Romina A Guedes, Pedro M P Fernandes, Natália Aniceto, Jorge A R Salvador, Maria João Gama, Rita C Guedes
Revisiting Proteasome Inhibitors: Molecular Underpinnings of Their Development, Mechanisms of Resistance and Strategies to Overcome Anti-Cancer Drug Resistance. Molecules (Basel, Switzerland) 27 (7) (2022)
Bruno M F Gonçalves, Vanessa I S Mendes, Samuel M Silvestre, Jorge A R Salvador
Design, synthesis, and biological evaluation of new arjunolic acid derivatives as anticancer agents. RSC medicinal chemistry 14 (2) (2022)
André T S Vicente, Jorge A R Salvador
MDM2-Based Proteolysis-Targeting Chimeras (PROTACs): An Innovative Drug Strategy for Cancer Treatment. International journal of molecular sciences 23 (19) (2022)
Judite R M Coimbra, Jorge A R Salvador
A patent review of glutaminyl cyclase inhibitors (2004-present). Expert opinion on therapeutic patents 31 (9) (2021)
Judite R M Coimbra, Salete J Baptista, Teresa C P Dinis, Maria M C Silva, Paula I Moreira, Armanda E Santos, Jorge A R Salvador
Combining Virtual Screening Protocol and In Vitro Evaluation towards the Discovery of BACE1 Inhibitors. Biomolecules 10 (4) (2020)
Ana S C Valdeira, Emad Darvishi, Girma M Woldemichael, John A A Beutler, Kirk R Gustafson, Jorge A R Salvador
Madecassic Acid Derivatives as Potential Anticancer Agents: Synthesis and Cytotoxic Evaluation. Journal of natural products 82 (8) (2019)
Romina A Guedes, Natália Aniceto, Marina A P Andrade, Jorge A R Salvador, Rita C Guedes
Chemical Patterns of Proteasome Inhibitors: Lessons Learned from Two Decades of Drug Design. International journal of molecular sciences 20 (21) (2019)